Krka DD (FRA:KN8) Total Receivables: €744 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:KN8 Krka DD FRA:KN8
66 GF Score
Price €269.00
GF Value €148.66
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Krka DD Total Receivables?

Krka DD FRA:KN8 +3.07% 66 Total Receivables is €744 Mil as of Mar. 2026. GuruFocus rates FRA:KN8 with a GF Score™ of 66/100 and a GF Value™ of €148.66 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Krka DD's Total Receivables for the quarter that ended in Mar. 2026 was €744 Mil.

Krka DD Total Receivables Historical Data

* Premium members only.

The historical data trend for Krka DD's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Krka DD Total Receivables Chart

Krka DD Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 690.90 436.09 546.70 591.76 648.84

Krka DD Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 646.86 672.20 661.56 648.84 744.49
FRA:KN8
66GF Score
Krka DD FRA:KN8
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Krka DD Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of €744 Mil mean?
Krka DD (FRA:KN8) has a Total Receivables of €744 Mil as of Mar. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Krka DD and its competitors.
Is Krka DD's Total Receivables too high?
Krka DD's current Total Receivables is €744 Mil. Overall, Krka DD has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Krka DD's Total Receivables compare to ZTS and UTHR?
Krka DD's Total Receivables of €744 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Drug Manufacturers company?
A good Total Receivables depends on the Drug Manufacturers industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Krka DD and its competitors. Krka DD's current Total Receivables is €744 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Krka DD stock overvalued right now?
Based on GuruFocus' analysis, Krka DD (FRA:KN8) is currently considered Significantly Overvalued. The stock's GF Value™ is €148.66, compared to a current price of €269.00 — trading 80.9% above its estimated fair value. The current Total Receivables is €744 Mil. Krka DD's overall GF Score™ is 66/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Krka DD (FRA:KN8), the current Total Receivables is €744 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Krka DD (FRA:KN8) Overvalued in 2026?

Based on GuruFocus' analysis, Krka DD stock appears to be overvalued. The current stock price of €269.00 is trading 80.9% above its estimated GF Value™ of €148.66. GuruFocus considers Krka DD to be Significantly Overvalued.

Key valuation signals for FRA:KN8:

  • Total Receivables: €744 Mil
  • GF Value™: €148.66 vs. price of €269.00 (80.9% above fair value)
  • GF Score™: 66/100 with 6 warning signs

No single metric tells the full story. See the FRA:KN8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Krka DD Business Description

Address Smarjeska Cesta 6, Novo Mesto, SVN, 8501
Krka DD engages in the development, production, marketing, and sales of human health products (prescription pharmaceuticals and non-prescription products), animal health products, health resorts, and tourist services. The company's products in Prescription pharmaceuticals include Cardiovascular diseases, Infections, and Oncology; Non-prescription products include Cold and cough products, nasal products, vitamins and minerals, and hair care products; and Animal health products include Antimicrobials and disinfectants, among others. It operates across the European Union, South-East Europe, Eastern Europe region, and Others. The company derives a majority of its revenue from the European Union.
66GF Score

Get the complete analysis for FRA:KN8

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€269.00
Price
€148.66
GF Value